Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).~2. Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.~Exclusion Criteria:~1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): 125 mg three times daily (375 mg per day) by mouth
- Gefitinib (Type: ACTIVE_COMPARATOR): 250 mg every 24 hours by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).